Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. - Noureddin M; Harrison SA; Loomba R; Alkhouri N; Chalasani N; Sheikh MY; Tomah S; Gutierrez JA; Urbina S; Suschak JJ; Brown R; Odili O; et al. (Lancet (London, England), 2025)